Evidence map›Paper›PMID 40459582›Full record

ArticleApplied microbiology and biotechnology2025

Inhibitory effect of recombinant BCG containing the fusion gene BFNA on EB virus-positive tumors.

Shuo Huang, Shuyang Shao, Liding Fan, Junying Wang, Furen Meng, Siyuan Guan, Changhao Wang, Ang Liu, Yuanhui Wang, Qingjie Xue

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Applied microbiology and biotechnology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Shuo Huang *School of Basic Medical, Jining Medical University, Jining, 272067, Shandong, China.
Shuyang Shao *School of Basic Medical, Jining Medical University, Jining, 272067, Shandong, China.
Liding FanClinical Medical College, Jining Medical University, Jining, 272067, Shandong, China.
Junying WangClinical Medical College, Jining Medical University, Jining, 272067, Shandong, China.
Furen MengClinical Medical College, Jining Medical University, Jining, 272067, Shandong, China.
Siyuan GuanClinical Medical College, Jining Medical University, Jining, 272067, Shandong, China.
Changhao WangPeking University Cancer Hospital and Institute, Beijing, 100142, China.
Ang LiuSchool of Basic Medical, Jining Medical University, Jining, 272067, Shandong, China. liuang08@163.com.
Yuanhui WangCollege of Rehabilitation Medicine, Jining Medical University, Jining, 272067, Shandong, China. iamwyh@sina.com.
Qingjie XueSchool of Basic Medical, Jining Medical University, Jining, 272067, Shandong, China. qjxue9797@mail.jnmc.edu.cn.ORCID http://orcid.org/0000-0001-5561-4091

Funding

Department of Science and Technology of Shandong Province J17KB085Department of Science and Technology of Shandong Province J18KA267Jining Medical University Students' platform for innovation and entrepreneurship training program cx2023068zNatural Science Foundation of Shandong Province 2018GCF118137Natural Science Foundation of Shandong Province ZR2019MH100Project of High-level Teachers in Beijing Municipal Universities in the Period of 13th Five-year Plan JYGC2023KJ017Shandong Medical and Health Technology Development Plan Project 2017WS339
6 · The paper itself

Abstract

To obtain recombinant Bacillus Calmette-Guérin (rBCG) containing an Epstein-Barr virus (EBV) fusion gene that can inhibit EBV-positive cancer, we obtained BZLF1 and EBNA1 cDNA and overlapped these sequences to assemble the fusion gene BFNA. Then, BFNA was inserted into pMV261, and pMV-BFNA was transfected into BCG-competent cells. Western blotting was performed to detect the target fusion protein, specific antibodies were detected in the serum via enzyme-linked immunosorbent assays (ELISAs), and spleen cell-specific cytokines were detected via enzyme-linked immunospot (ELISPOT) assays. Cytotoxic T lymphocyte (CTL) activity, tumor weight, tumor formation time, and mouse survival were determined in EBV-positive tumor cell (NPRC18) cancer models, and flow cytometry was performed to analyze the quantities of CD8

Indexed as

BCG VaccineHerpesvirus 4, HumanMycobacterium bovisNeoplasmsAnimalsAntibodies, ViralCD8-Positive T-LymphocytesCell Line, TumorDisease Models, AnimalFemaleMiceMice, Inbred C57BLRecombinant Fusion ProteinsT-Lymphocytes, CytotoxicAntibodies, ViralBCG VaccineRecombinant Fusion ProteinsEBV-positive tumorFusion gene BFNARBCG

Identifiers

PMID40459582
PMCPMC12133901

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.